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System immunology-based identiﬁcation of blood
transcriptional modules correlating to antibody responses in
sheep
Roman Othmar Braun 1,2,3, Livia Brunner4, Kurt Wyler5, Gaël Auray1, Obdulio García-Nicolás1,3, Sylvie Python1,3, Beatrice Zumkehr1,
Véronique Gaschen6, Michael Hubert Stoffel6, Nicolas Collin4, Christophe Barnier-Quer4, Rémy Bruggmann5 and Artur Summerﬁeld1,3
Lacking immunogenicity, inactivated vaccines require potent adjuvants. To understand their effects, we used a system
immunology-based analysis of ovine blood transcriptional modules (BTMs) to dissect innate immune responses relating to either
antibody or haptoglobin levels. Using inactivated foot-and-mouth disease virus as an antigen, we compared non-adjuvanted to
liposomal-formulated vaccines complemented or not with TLR4 and TLR7 ligands. Early after vaccination, BTM relating to myeloid
cells, innate immune responses, dendritic cells, and antigen presentation correlated positively, whereas BTM relating to T and
natural killer cells, as well as cell cycle correlated negatively with antibody responses. Interestingly, BTM relating to myeloid cells,
inﬂammation and antigen presentation also correlated with haptoglobin, but in a reversed manner, indicating that acute systemic
inﬂammation is not beneﬁcial for early antibody responses. Analysis of vaccine-dependent BTM modulation showed that liposomal
formulations induced similar responses to those correlating to antibody levels, while addition of TLR ligands reduced myeloid cells,
inﬂammation and antigen presentation BTM expression despite promoting antibody responses. Furthermore, this vaccine was
more potent at downregulating T and natural killer cell BTM. When pre-vaccination BTM were analyzed, we found that high vaccine
responders expressed higher levels of cell cycle and myeloid cell BTMs as compared with low responders. In conclusion, we have
transferred human BTM to sheep and identiﬁed early vaccine-induced responses associated with antibody levels or unwanted
inﬂammation. Such readouts are applicable to other veterinary species and very useful to identify efﬁcient vaccine adjuvants, their
mechanism of action, and factors related to low responders.
npj Vaccines            (2018) 3:41 ; doi:10.1038/s41541-018-0078-0
INTRODUCTION
In the past, vaccines were developed empirically requiring many
animal studies with a long-term follow-up to assess vaccine
efﬁcacy. Furthermore, although the mechanisms of many vaccine
adjuvants at the molecular and cellular level are clear, in vivo
protection is much more complex and still difﬁcult to understand
and predict. Systems immunology offers powerful approaches
towards dissecting the early innate immune response relating to
potent adaptive immune responses in human.1–3 This enabled to
identify genes expressed in peripheral blood leukocytes within the
ﬁrst days after vaccination, which correlated to CD8 T-cell or
antibody responses.2,3 Nevertheless, a main problem with this
relatively simple approach was the high heterogeneity of
individual responders and the difﬁculty to understand immuno-
logical processes from individual gene information. For these
reasons, a much more powerful analysis of transcriptomic data
was developed by identifying gene sets such as blood transcrip-
tional modules (BTMs) through large-scale data integration.1,4 To
this end, Li et al.1 established human blood transcriptomes from
540 data series containing over 32,000 samples obtained from
many disease-related studies to identify master networks of genes
co-regulated and interacting in peripheral blood immune system
during many physiological and pathological conditions1. Certain
BTM were demonstrated to correlate with adaptive immune
responses in a vaccine type-speciﬁc manner enabling conclusions
on immunological processes associated with desired vaccine
responses.1
For foot-and-mouth disease (FMD), a devastating viral infection
affecting cloven-hooved animals, traditional vaccine approaches
are based on the formulation of inactivated antigen with
conventional adjuvants such as oil-in-water emulsions.5 In
countries free of FMD, besides culling infected herds, vaccines
can have an important role in the control of outbreaks.
Nevertheless, the ability to induce early protection is an essential
element of such vaccines. A problem associated with the
elimination of FMD from endemic areas is the fact that current
vaccines offer protection with a very limited duration of
immunity.6 A potential to improve such vaccines would be to
enhance their ability to activate the innate immune system by
targeting Toll-like receptors (TLRs), which can promote T-cell help
and differentiation of B lymphocytes into memory or long-lived
plasma cells.7 TLR are a family of pathogen recognition receptors
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(PRR) typically expressed at high levels on specialized antigen-
presenting cells and are central for alerting the innate immune
system in case of infection. Cell surface TLRs, such as TLR4,
recognize microbial pattern molecules such as bacterial lipopoly-
saccharides, whereas endosomal TLRs such as TLR7 and
TLR9 sense single-stranded RNA or microbial unmethylated DNA
with many CpG motifs, respectively. In fact, TLR4 and TLR7 ligands
were shown to strongly enhance antibody responses in the mouse
model,7 and were therefore selected for the present study.
Based on this, one aim of this work was to determine the
potential of such TLR ligands to improve the immunogenicity of
an inactivated vaccine in large animals using an FMD vaccine as a
model. We used sheep as a model for an ungulate that is naturally
susceptible to FMD virus (FMDV). Although in western countries
small ruminants usually are not considered in vaccination
program, the immune system of sheep and cattle are relatively
similar and the use of sheep requires less space and ﬁnancial
resources. Furthermore, in certain areas of the world small
ruminant represent the main FMD-susceptible livestock and can
play an important role for spreading the infection during
outbreaks.8–10
Our second important aim was to transfer human BTMs to the
sheep model and identify gene sets correlating with antibody
levels as well as vaccine side effects. We also successfully
employed this bioinformatics pipeline to characterize vaccine-
adjuvant-dependent modulation of the immune responses as well
as the pre-vaccination transcriptome associated with high
immune responses.
RESULTS
Antibody responses
Three groups of sheep were vaccinated with FMDV antigen
formulated either in buffer (PBS), in liposomes (L) or in liposomes
containing TLR4 and TLR7 ligands (L(TLRL)), (Fig. 1a) and the ability
of the vaccines to induce an early neutralizing antibody response
was tested (Fig. 1b). For the physicochemical characterization of
the vaccines see Supplementary Fig. 1. All groups responded to
vaccination when day 0 p.v. (D0) was compared to D7, D14 and
D28 using ratio-paired T tests (p < 0.05). Only the L(TLRL) group
was able to signiﬁcantly enhance the antibody levels above the
levels of the PBS group, at D7, D14 and D28 (Fig. 1b). At D28, the L
(TLRL) group had signiﬁcantly higher levels of antibodies
compared to the L group (Fig. 1b).
Vaccine-induced haptoglobin and transcriptional modulations
As liposomal formulations caused lameness in some animals for
1–2 days after injection, we also quantiﬁed systemic inﬂammation
by measuring serum haptoglobin, an acute-phase protein induced
in the liver by pro-inﬂammatory cytokines,11 and which represents
a sensitive marker of inﬂammation following sheep vaccination.12
Our results demonstrate that liposomal formulations were indeed
associated with an acute-phase response peaking at D3 and still
detectable in most animals at D7 (Fig. 1c). Interestingly, the TLRL
did not enhanced but actually reduced this response (p= 0.038
for L versus L(TLRL) at D3).
Also at the transcriptional level, the liposomal formulations
caused a stronger perturbation of the immune system, but this
was dampened by the addition of TLRL (Fig. 1d). For example,
when comparing and peripheral blood mononuclear cells (PBMCs)
before and at D3 (D0 vs. D3), PBS induced the signiﬁcant
upregulation of 250 genes, L of 462 genes, and L(TLRL) only of 43
genes. Nevertheless, at D7, the TLRL-adjuvant group had clearly
the most up- or downregulated transcripts (Fig. 1d and
Supplementary Fig. 2). We found 150 common genes between
the L and L(TLRL) groups, and 120 common genes for the L and
PBS groups and seven common genes for all three formulations.
Individual transcripts correlating with neutralizing antibody titers
Individual changes in gene expression were calculated and
correlated with the SNT on day 7, 14, and 28 p.v. (Supplementary
Fig. 3). For the D0 vs. D3 differentially expressed genes, 26
transcripts (ZNF646, STIM2, C9orf3, NPEPPS, SDR39U1, HEXDC,
NUCB2, GHDC, LSR, MYO1E, TRAPPC6A, DCAF12, ABCC2,
ZDHHC24, TRIM41, GZMA, NAGK, GMNN, OLFML3, MYO7A,
TNFSF13B, GGA3, ASB8, ARNTL, GNG3, PLA2G12A) were identiﬁed
to correlate with the SNT of all three time points (7, 14, and
28 days). For the D0 vs. D7 differentially expressed genes, six
transcripts were found to correlate with SNT of all three time
points (CHPT1, RPL12, RNASEL, CCDC93, MFAP2, MYO1E). Only
MYO1E was correlating at D3 as well as D7 with the SNT at all time
points.
Translation of human BTM to the sheep
While some of the genes identiﬁed above are clearly linked to
antibody responses such as TNFSF13B (B-cell-activating factor),
the potential involvement of most genes in promoting antibody
responses remained elusive. We therefore employed gene set
enrichment (GSEA) using BTM developed in the human system.
These have been demonstrated to provide a comprehensive
picture of human immune responses correlating with adaptive
immune responses induced by different classes of vaccines.1 To
this end the gene composition of the BTM was adapted to sheep
by replacing genes known to differ in name for human and sheep
such as those belonging to the MHC, CD1, TCR, Ig and IFN families
with sheep homologues. In addition, we manually annotated
many sheep genes focussing on those represented in many BTM.
This resulted in a median coverage of 88.2% (Supplementary Fig.
4). The list of all BTM with their gene compositions can be
downloaded from the Supplementary Data.
BTM correlating with antibody responses
The correlation of BTM with antibody responses measured at 7, 14,
and 28 days p.v. were determined for the D3 and D7
transcriptome (Fig. 2). Although some BTM correlated only with
one of the time points p.v., other correlated with two or all of the
time points analyzed. This was expected as some animals with low
early antibody levels caught up at day 28 p.v. (Fig. 1b).
Nevertheless, for D3 the BTM M209 (lysosome) and M23 (RA,
WNT, CSF receptor network) positively correlated with the SNT at
all time points. Furthermore, despite the variation in antibody
responses over time, a number of BTM were found that negatively
correlated to antibody responses measured at all three time
points. These were mainly BTM related to cell proliferation (M4.10,
M37.3, M10.0, M182) and T/natural killer (NK) cells (M7.2, M61.2,
M7.3).
Antibody-correlating D7 BTM were reduced in numbers (Fig. 2).
Nevertheless, some BTM were found again, including M146 (MHC-
TLR7-TLR8 cluster, positive correlation), M40 (complement and
other receptors, positive correlation), M35.0/M35.1 (signaling in
T cells, negative correlation) and M230 (cell cycle, mitotic phase,
negative correlation, S1 (NK cell surface signature, negative
correlation), S3 (plasma cell surface signature, negative correla-
tion) and a number of unnamed BTM (M102, M116, M177 and
M249). BTM 7.4 (T cell activation, positive correlation) was the only
BTM found with inverse correlation).
To enable an easier interpretation of the BTM results, we
classiﬁed them into six BTM families (Table 1 and Supplementary
Excel ﬁle “BTM composition and families”). To this end, BTM were
attributed to immune cell types or immunological processes, for
which we decided to make large families to obtain a simpliﬁed
synopsis of early immune responses correlating to antibody titers.
As an example, the BTM family “myeloid cells/inﬂammation” was
composed of all BTM’s relating to monocytic cells, neutrophils, and
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Fig. 1 Neutralizing antibodies, haptoglobin and differentially expressed genes in PBMC induced by vaccination. a Study design. b Serum
neutralizing antibody titers following vaccination of sheep with antigen in phosphate buffered saline (PBS), antigen formulated in liposomes
(L) and antigen formulated in liposomes with TLRL (L(TLRL)). c Vaccine-induced haptoglobin responses. d Vulcano plots showing differentially
expressed genes which were up- or downregulation on day 3 (D3) and day 7 (D7) compared with before immunization, respectively. Green
dots represent signiﬁcant genes (p adjusted < 0.05). Digits in the plots indicate the number of signiﬁcantly down or upregulated genes. In b
and c, statistical signiﬁcant differences between two groups were calculated using unpaired two-way ANOVA with repeated measures
followed by Tukey’s multiple comparisons test (***p < 0.001; **p < 0.002; *p < 0.033)
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other elements of inﬂammatory reactions. We also included BTM
related to coagulation and complement activation, as these are
processes induced during inﬂammation (Table 1). The result of
such an analysis for the correlating BTM is shown in Fig. 3 and
demonstrate that the D3 dominant BTM families positively
correlating with antibody responses were “myeloid cells/inﬂam-
mation” and “DC/antigen presentation,” whereas the BTM families
“T/NK cells” and “cell cycle” were the most prominent to
negatively correlate. This dominance was seen in terms of the
number of correlating BTM’s attributed to the family for each of
a Correlating BTM D0 vs D3 b Correlating BTM D0 vs D7
viral sensing & immunity; IRF2 targets network (I) (M111.0)
TLR8−BAFF network (M25)
TBA (M79)
TBA (M66)
TBA (M249)
TBA (M243)
TBA (M221)
TBA (M184.1)
TBA (M177.0)
TBA (M116)
TBA (M104)
TBA (M102)
targets of FOSL1/2 (M0)
T cell surface signature (S0)
T cell differentiation via ITK and PKC (M18)
T cell differentiation (Th2) (M19)
T cell differentiation (M14)
T cell activation and signaling (M5.1)
T cell activation (III) (M7.4)
T cell activation (II) (M7.3)
T cell activation (I) (M7.1)
spliceosome (M250)
signaling in T cells (II) (M35.1)
signaling in T cells (I) (M35.0)
Rho GTPase cycle (M4.14)
Resting dendritic cell surface signature (S10)
Ran mediated mitosis (M15)
RA, WNT, CSF receptors network (monocyte) (M23)
PLK1 signaling events (M4.2)
plasma cells, immunoglobulins (M156.1)
Plasma cell surface signature (S3)
nucleotide metabolism (M181)
NK cell surface signature (S1)
Naive B cell surface signature (S8)
myeloid cell enriched receptors and transporters (M4.3)
myeloid cell cytokines, metallopeptidases and laminins (M78)
mitotic cell division (M6)
mitotic cell cycle in stimulated CD4 T cells (M4.9)
mitotic cell cycle in stimulated CD4 T cells (M4.5)
mitotic cell cycle in stimulated CD4 T cells (M4.11)
mitotic cell cycle − DNA replication (M4.4)
mismatch repair (II) (M22.1)
mismatch repair (I) (M22.0)
MHC−TLR7−TLR8 cluster (M146)
lysosome (M209)
lysosomal/endosomal proteins (M139)
lipid metabolism, endoplasmic reticulum (M92)
integrins and cell adhesion (M84)
integrin mediated leukocyte migration (M39)
IL2, IL7, TCR network (M65)
extracellular matrix, collagen (M210)
enriched in T cells (I) (M7.0)
enriched in NK cells (receptor activation) (M61.2)
enriched in NK cells (I) (M7.2)
enriched in neutrophils (I) (M37.1)
enriched in myeloid cells and monocytes (M81)
enriched in monocytes (IV) (M118.0)
enriched in monocytes (II) (M11.0)
enriched in G−protein coupled receptors (M130)
enriched in DNA interacting proteins (M182)
enriched for promoter motif NATCACGTGAY (M178)
endoplasmic reticulum (M37.2)
E2F1 targets (Q4) (M10.1)
E2F1 targets (Q3) (M10.0)
DNA repair (M76)
cytokines − recepters cluster (M115)
complement and other receptors in DCs (M40)
complement activation (II) (M112.1)
complement activation (I) (M112.0)
chemokines and receptors (M38)
cell division stimulated CD4+ T cells (M46)
cell division in stimulated CD4 T cells (M4.6)
cell division (M37.3)
cell division − E2F transcription network (M4.8)
cell cycle, mitotic phase (M230)
cell cycle (III) (M103)
cell cycle (II) (M4.10)
cell cycle (I) (M4.1)
CD4 T cell surface signature Th1−stimulated (S6)
blood coagulation (M11.1)
antigen processing and presentation (M200)
−0.4
0.0
0.4
Rsquare
7 14 28
translation initiation factor 3 complex (M245)
transcription regulation in cell development (M49)
transcription elongation, RNA polymerase II (M234)
TBA (M93)
TBA (M249)
TBA (M242)
TBA (M229)
TBA (M220)
TBA (M205)
TBA (M197)
TBA (M193)
TBA (M177.0)
TBA (M161)
TBA (M116)
TBA (M114.0)
TBA (M102)
T cell activation (III) (M7.4)
signaling in T cells (II) (M35.1)
signaling in T cells (I) (M35.0)
respiratory electron transport chain (mitochondrion) (M216)
recruitment of neutrophils (M132)
platelet activation and degranulation (M85)
platelet activation & blood coagulation (M199)
plasma membrane, cell junction (M162.0)
plasma cells, immunoglobulins (M156.1)
nuclear pore, transport; mRNA splicing, processing (M143)
NK cell surface signature (S1)
MHC−TLR7−TLR8 cluster (M146)
formyl peptide receptor mediated neutrophil response (M11.2)
extracellular region cluster (GO) (M189)
extracellular matrix, complement (M140)
enriched in B cells (III) (M47.2)
enriched in B cells (II) (M47.1)
enriched for unknown TF motif CTCNANGTGNY (M62.1)
cytoskeleton/actin (SRF transcription targets) (M145.0)
complement and other receptors in DCs (M40)
cell junction (M162.1)
cell cycle, mitotic phase (M230)
cell activation (IL15, IL23, TNF) (M24)
B cell development/activation (M58)
B cell development (M9)
7 14 28
day day
Fig. 2 BTM correlating to serum neutralizing antibody titers. a Heatmap showing the correlation of D3 BTM with antibody levels on day 7, 14,
or 28 after immunization. Animals from all groups were included (n= 18, cutoff p < 0.05). b Heatmap showing the correlation of D7 BTM with
antibody levels in analogy to a
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the analyses. The polar plots created for day 7 did not enable the
identiﬁcation of clearly dominant BTM families because of the
reduced number of correlating BTMs. Interestingly, at this later
time point the BTM family “myeloid cells/inﬂammation” was
negatively correlating with antibody levels.
Vaccine-induced BTM’s
We next calculated BTM’s signiﬁcantly induced by the different
vaccines with the aim to compare these responses with the
antibody-correlating BTM, and to determine the effects of
formulation and TLRL. The results are shown as BTM families in
Fig. 3b and as heatmap for individual BTM in Supplementary Fig.
5. In the PBS group, only few BTM were signiﬁcantly modulated at
both D3 and D7. On D3 the liposomal formulations strongly
promoted “myeloid cells/inﬂammation” and “DC/antigen presen-
tation” but downregulated “T/NK cells” and “cell cycle” BTM
families, creating a picture resembling the correlation data shown
in Fig. 3a. Interestingly, the addition of the TLRL abrogated the
induction of “myeloid cells/inﬂammation” and “DC/antigen pre-
sentation” BTM. In contrast, on D7 we only found many
signiﬁcantly modulated BTM in the L(TLRL) group. While “myeloid
cells/inﬂammation” and “DC/antigen presentation” were down-
regulated, the “B cell” and “cell cycle” family was found to be
upregulated only in the TLRL group.
As a main aim of the present study was to identify modules
induced by our vaccine formulation and correlating with antibody
response we combined the data of Fig. 3 to search for BTM which
would correlate to the antibody response and also be induced by
a particular vaccine. This approach was also used to identify BTM
correlating independent from the vaccine-induced responses.
Figure 4 shows average correlations coefﬁcients for BTM which
signiﬁcantly correlated with antibody responses found at least for
two different time points. The BTM were grouped in BTM which
were not found to be induced by a vaccine (“only corr.”), which
were induced by the PBS-formulated vaccine (corr & PBS), by the
liposomal formulation (corr. & L) or by the TLRL-adjuvanted
liposomal vaccine (corr. & L(TLRL)). On D3, for many BTM such as
those belonging to the “DC/antigen presentation” and “B cells”
families, correlating BTM were actually not identiﬁed to be
signiﬁcantly induced by the vaccines, indicating that these could
more reﬂect differences in the host response to the vaccination.
The L vaccine group induced many correlating “myeloid cells/
inﬂammation” BTM, while the L(TLRL) group was potent at
downregulating “T/NK cell” BTM (Fig. 4a). Overall, this demon-
strated a strong immunomodulatory effect of the TLRL. On D7,
none of the correlating BTM were not found to be induced by the
vaccines (Fig. 4b), again indicating that these BTM reﬂect
differences in the host responses to the vaccines.
Impact of vaccines on peripheral blood mononuclear cell
populations
Considering that changes in many BTMs could have been the
result of a modulation of relative frequencies of cell populations
we quantiﬁed CD14+ and CD16+monocytes as well as CD4+ and
CD8+ T cells in D0 and D3 PBMC. Only a signiﬁcant reduction of
CD8+ T cells was found in the L and L(TLRL) groups
(Supplementary Fig. 6), indicating that the vaccine-induced BTM
modulation is not solely reﬂecting changes in the cellular
composition of the PBMC.
BTM correlating to the acute phase response
To differentiate innate immune responses associated with anti-
body responses or unwanted inﬂammation, we calculated the
correlation of BTM with the haptoglobin responses (Fig. 5 and
Supplementary Fig. 7). We excluded the PBS group as no
haptoglobin responses were found in these animals (Fig. 1c). For
the D3 transcriptome, many negative correlations were found for
the “myeloid cells/inﬂammation” and “DC/antigen presentation”
but positive correlation for the “T/NK cells” and “cell cycle” BTM. In
addition, a few “B cells”, “cell cycle” and “others” BTM families were
negatively correlated. For the haptoglobin responses on day 7 p.v.,
the dominant modulation was again in the “myeloid cells/
inﬂammation” BTMs. For the D7 transcriptome the number of
correlations was markedly reduced. If BTM families are compared
with those correlating with antibody levels measured at D3, we
found that “myeloid cells/inﬂammation” and “DC/antigen pre-
sentation” BTM families were regulated in an opposite manner.
When looking at individual BTM (D0 vs D3), only seven out of 93
correlated in the same direction to the antibody responses (M130,
M61.2, M210, M65, M39, M14, M0, Supplementary Fig. 7 and Fig.
2). Five correlated in an opposite manner (M11.1, M22.0, M181,
M23, M111.0). These results indicate that the host responses
associate with the acute phase response are largely not linked to
those resulting in potent antibody responses.
Table 1. Deﬁnition and composition of BTM families
BTM families Immune cells and processes BTM included
Myeloid cells/
inﬂammation
Myeloid cells, innate/inﬂammatory response (inﬂammatory
cytokines and chemokines), leukocyte migration, coagulation and
platelet activation, complement activation
M0, M4.3, M4.15, M11.0, M11.1, M11.2, M16, M21, M23,
M24, M27.0, M27.1, M29, M33, M37.1, M38, M39, M45,
M53, M59, M73, M78, M81, M85, M86.0, M86.1, M88.0,
M91, M112.0, M112.1, M115, M118.0, M118.1, M132, M163,
M199, S4, M30, M32.0, M32.1, M37.0, M42
DC/antigen
presentation
DC surface (resting and activated), antigen processing and
presentation, DC activation
M5.0, M25, M28, M40, M43.0, M43.1, M50, M64, M67, M71,
M87, M95.0, M95.1, M119, M138, M139, M146, M165,
M168, M200, M209, S5, S10, S11
T/NK cells NK and T-cell surface, differentiation, activation, signaling, co-
stimulation, and proliferation
M4.5, M4.6, M4.9, M4.11, M5.1, M7.0, M7.1, M7.2, M7.3,
M7.4, M12, M14, M18, M19, M35.0, M35.1, M36, M44, M46,
M52, M61.0, M61.1, M61.2, M65, M126, M157, M223, S0,
S1, S6, S7
B cells B cells, BCR signaling, B-cell development and differentiation,
plasma cells, immunoglobulins
M9, M47.0, M47.1, M47.2, M47.3, M47.4, M58, M69, M83,
M123, M156.0, M156.1, M217, S2, S3, S8, S9, M152.0,
M152.1, M152.2, M182
Cell cycle Cell cycle, proliferation, DNA repair, nucleotide and amino acid
metabolism, splicing
M76, M103, M4.10, M4.12, M4.0, M4.1, M4.2, M4.4, M4.7,
M4.8, M6, M8, M10.0, M10.1, M20, M22.0, M22.1, M31,
M32.2, M32.4, M37.3, M49, M144, M167, M175, M181,
M230, M250, M15, M143, M154.0, M169
IFN type-I Nucleic acid sensing, IFN type-I induction, and IFN response
signature
M13, M68, M75, M111.0, M111.1, M127, M150, M158.0,
M158.1
System immunology-based identiﬁcation of blood transcriptional
R.O. Braun et al.
5
Published in partnership with the Sealy Center for Vaccine Development npj Vaccines (2019)    41 
Pre-vaccination BTM associated with antibody levels
Considering the heterogeneity of vaccine-induced antibody
responses (Fig. 1b), we tested if certain BTM measured before
vaccination would be associated with higher levels of antibody
response. To this end, in each vaccine group animals having an
SNT at day 28 of > 50% above the median were deﬁned as “high
responders” (n= 6) and those with < 50% of the median as “low
responders” (n= 6). A comparison of high and low responders
Fig. 3 BTM families correlating with antibody responses and induced by the vaccines. BTM families were created as described in Table 1. a The
polar plots show the correlation coefﬁcients for BTM of the module families with signiﬁcant positive or negative correlation to neutralizing
antibody levels in serum (p < 0.05). BTM for the D3 (upper plots) and D7 (lower plots) transcriptome are shown. b Vaccine-dependent BTM
modulations were calculated as normalized enrichment scores (NES) using GSEA. The signiﬁcantly (p < 0.05) modulated BTM were grouped as
BTM families as in a. The data are shown was calculated for each vaccine group with the D3 (upper plots) and D7 (lower plots) transcriptome
System immunology-based identiﬁcation of blood transcriptional
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using GSEA demonstrated that 10 BTM related to cell cycle and
DNA repair, four BTM related to myeloid cells, two BTM related to
inﬂammation and innate immune responses, one to NK cells were
expressed at relatively higher levels in the “high responders”
(Fig. 6). No BTM was higher in the “low responder” animals.
DISCUSSION
The present study adapted BTM originally developed for human
blood to sheep PBMC to understand vaccine-induced responses
correlating with antibody and acute-phase responses. For efﬁcient
delivery to antigen-presenting cells, we employed synthetic
Fig. 4 Relationship of BTM correlating to antibody levels and their induction by the vaccines. The heatmap shows the average correlation
coefﬁcient r2 from BTM correlating to antibodies at least at two different time points. BTM correlating to antibody levels at all time points (day
7, 14 and 28) are indicated in bold letters. BTMs were allocated to BTM families deﬁned in Table 1 and grouped as BTM which were not
induced by any of the vaccine group (only corr.), induced by the PBS-based vaccine (corr. & PBS), the L (corr. & L) or the L(TLRL) vaccines (corr.
& L(TLRL); for data on vaccine-induced BTM see Supplementary Fig. 4). The blank cells indicate that there was no signiﬁcant correlation for this
time point post vaccination
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liposomes as vaccine platform and tested the effect of a
combination of TLR4 and TLR7 ligands on antibody and acute-
phase protein response. These ligands were selected based on
their synergistic potentiation of antibody responses in a mouse
model.7 Speciﬁcally, the TLR7 ligand Gardiquimod was selected
based on its ability to induce proliferation and induce IFN-α in
PBMC,13,14 and the TLR4 ligand monophosphoryl lipid A (MPLA)
based on its potent triggering of nuclear factor-κB signaling,
which promotes pro-inﬂammatory responses in mononuclear
phagocytes.15,16 Furthermore, MPLA is clinically approved and
was also recently reported to induce a similar response in sheep
compared with human PBMC.17 The vaccination of sheep was
successful in terms of induction of neutralizing antibody titers to
levels likely associated with protective immunity.18–20 As antici-
pated, the addition of the TLRL signiﬁcantly enhanced the
responses. Nevertheless, it is clear that the present vaccine still
requires signiﬁcant improvements, and thus future studies
focussing on the effects of formulation, TLR ligand selection and
dose in sheep are needed.
Interestingly, although the increase in antibody responses
induced by the TLRL was weak compared to previous studies in
mice,7 it had a clear effect on the expression of individual genes.
Strikingly, the overall perturbation of gene expression was
reduced at D3 in terms of differentially up- or downregulated
genes when compared with the L group. Furthermore, on day
three p.v., the PBS group shared many upregulated genes with the
L, but not with the L(TLRL) group. At day 7, this was even more
evident in that differentially regulated genes were found almost
exclusively in the TLRL group. Also, comparing the vaccine groups
using BTM conﬁrmed clear effects of the TLRL. The reduction of
upregulated “myeloid cells/inﬂammation” and DC/antigen pre-
sentation” BTM at D3 together with the above reduced perturba-
tion of individual genes and the reduced induction of haptoglobin
indicates an anti-inﬂammatory effect of the TLRL. Future studies
are required to understand how this is induced and if it is an effect
of one of the TLRL or their combinations. The fact that at D7 the L
(TLRL) group showed the strongest perturbations, both at the
individual gene and BTM level, demonstrates that this is not a
simple suppressive effect but that rather long-lasting immuno-
modulatory circuits are induced.
The analysis of genes correlating positively or negatively with
antibody titers revealed a relatively large number of genes. We
focused mainly on those found to correlate at least for two
different time points to increase the chance to have truly relevant
genes. Nevertheless, for most of the correlating genes, their role in
immune responses is unclear, with the exception of TNFSF13B
representing BAFF. Furthermore, only few of the correlating genes
matched those identiﬁed in PBMC from humans vaccinated with
an inactivated viral vaccine.2 For these reasons, we employed the
BTM as a much more powerful bioinformatics analysis of
transcriptomic data. BTM represent master networks of
Fig. 5 BTM families correlating to vaccine-induced haptoglobin levels. BTM families were created as described in Table 1. The polar plots show
correlation coefﬁcients for module families with signiﬁcant (p < 0.05) positive or negative correlation to serum haptoglobin levels. BTM families
for the D3 (upper plots) and D7 (lower plots) transcriptome are shown
Fig. 6 Pre-vaccination BTM associated with antibody levels. a GSEA
was used to determine the BTM enriched in “high responders” (n=
6, red) and “low responders” (n= 6, blue). The colors indicates the
NES. b Heatmap for the BTM “monocyte surface signature” (S4) as an
example of the analysis in a. Each square represents the indicated
gene expression for individual animals (same color code as in a)
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immunological genes strongly co-regulated and interacting
during many physiological and pathological conditions.1 This
approach permitted to identify many BTM expressed on D3 and
D7 correlating with antibody responses on day 7, 14, and 28 p.v.
Remarkably, many of the correlating BTMs were also found in
human vaccination studies using protein-based or inactivated
vaccines. Prominent amongst these are positively correlating BTM
relating to monocytes such as M11.0, M23, and M118,1,21–23 to
complement activation such as M112,1,23 to TLR/antigen pre-
sentation such as M146, M251,21,23. Among prominent negatively
correlating modules appearing in both human and sheep
vaccination studies is the NK cell signature BTM M61.1, M61.2,
and M61.318,20,21. In sheep, many T-cell modules including CD4 T-
cell BTM (M4.6, S6) as well as general T-cell activation modules
(M7.X) were negatively correlated with antibodies. Nevertheless,
the various reports on human studies indicate that this can
strongly vary depending on the time point being analyzed, the
vaccine employed, the number of vaccinations, and the age,1,23,24
although M7.1 and M7.2 were often negatively correlated with
antibody response also in human studies.1,21,23,24 Our phenotyp-
ing data conﬁrmed that at least for the CD8 T cells the liposomal
vaccine formulations induced a relative reduction of circulating
T cells. For the cell cycle modules which were also among the BTM
with a negative correlation in sheep, this was rarely found in the
human studies using protein-based vaccines, indicating possible
species differences or alternatively a speciﬁc effect of the
liposomal vaccine employed in the present study. Clearly, the
correlating BTM response strongly depends on the type of
vaccine.1 Altogether, we propose that the common correlating
BTM found for several different inactivated/protein-based vaccines
in both species could be particular robust measurements. From
our data, we also conclude that measuring the transcriptome early
after vaccines provides more correlating BTM and, therefore, more
information regarding the effects of the vaccine on the immune
system.
For the immunological interpretation of these results, it must be
considered that blood represents only a transit compartment for
immune cells. As a result of vaccine-induced innate immune
responses, haematopoiesis of myeloid cells and DC is likely to be
enhanced explaining the increase of many modules relating to
these cell types. Furthermore, it is obvious that despite the
intramuscular injection, the vaccines cause systemic inﬂammatory
effects, some of which obviously correlate with antibody
responses. These are not only a number of modules relating the
DC and antigen presentation but also to complement activation
and blood coagulation. With these reactions, it is also possible to
explain the negative correlation of T/NK cell modules, as these
cells are very quickly recruited to lymphoid tissues following acute
innate immune response such as virus infections.25 The negative
correlation of cell cycle BTM could be related to the same
mechanisms as T cell represent the main cell fraction in PBMC and
many such BTM were actually related to T cells, in particular CD4
T cells.
An important question arising from such studies is whether the
above BTM represent either mechanistically relevant modules,
non-functional correlates or even modules that also reﬂect
unwanted side effects of strong adjuvants. To address this
question, we performed two additional analyses, which were to
compare the correlating BTM with the vaccine-induced BTM, as
well as to identify BTM correlating with an acute-phase protein.
Our results demonstrate that many of the correlating BTM were
actually not identiﬁed to be signiﬁcantly induced by the vaccines,
indicating that these could more reﬂect differences in the host
response of individual animals to vaccination. Some BTM relating
to “DC/antigen presentation” and “cell cycle” appeared to be
particular interesting to identify individual variability due to their
strong correlation with antibody levels without apparently being
inﬂuenced by the vaccine. These analyses also permitted to
identify potent effects of the TLRL potentially involved in their
beneﬁcial action. While BTM related to “cell cycle” had a strong
negative correlation to antibodies they were strongly induced by
the L vaccine but not by L(TLRL) formulation. Similar observations
but as positive correlation/upregulation were made for some
“myeloid cells/inﬂammation” and “DC/antigen presentation” BTM.
In contrast, some “T/NK cells” BTM correlated negatively with
antibodies and were also downregulated by the L(TLRL) vaccine. It
will thus be interesting to address which of the above effect of the
TLRL, in particular the prominent effects on the T/NK cell modules,
are mechanistically relevant to better understand their mode of
action in promoting immune responses.
The main difference with the PBS group was that it did not
impact the “T/NK cell” BTM and had an opposite effect
(upregulation) on the “cell cycle” BTM. We speculate that in the
absence of liposomal formulation the inﬂammatory responses and
the presence of antigen-loaded activated DC in draining lymph
nodes could be reduced explaining a reduced recruitment of
these cells to lymphoid tissue.
The comparison of the BTM correlation analyses to antibodies
and haptoglobin levels indicated that the host responses associate
with the acute phase response are largely not linked to those
resulting in potent antibody responses. In particular, the BTM
families “myeloid cells/inﬂammation” and “DC/antigen presenta-
tion” were found to correlate in a opposite manner at 3 days p.v.
Finally, we also tested whether different pre-vaccination
expression levels of BTM can be identiﬁed in low or high
antibody-producing sheep. Our data indicate that this seems
possible even with relatively small group sizes, although
additional work is required for conﬁrmation. The relative
upregulation of cell cycle, monocyte, DC and innate/inﬂammatory
response BTM in the “high responders” would indicate that the
immune system of those animals is in a kind of pre-activated
status. A possible explanation for the combination of increased
levels of myeloid cell/DC and cell cycle BTM could be increased
hematopoiesis and egress of cells from the bone marrow and
thymus. Future studies could aim at inducing such a status to
enhance vaccine-induced responses.
Obviously, there many other possibilities to analyze gene sets
and a choice from a multitude of possible gene sets, including
pathways and molecular network-based gene sets,26,27 must be
made. An example for a different approach selected in cattle is the
study by Laughlin et al. using established canonical pathways and
gene ontology networks analyzed using a method called Dynamic
Bayesian Gene Group Activation.28 Although many of the gene
sets identiﬁed to correlate are related to those found using the
BTM method, a direct comparison is difﬁcult. To enable a
comparison of our data with a relatively large set of human
vaccination data, we selected the BTM method for the present
study.
In conclusion, the present work has developed a system
immunology readout in the ovine model composed of many
immunologically relevant gene expression networks, which
correlate with antibody responses. We anticipate that this is
applicable to other species and will be very useful to both the
identiﬁcation of efﬁcient vaccine adjuvants causing little
unwanted side effects and to ﬁnd factors related to low vaccine
responders.
METHODS
Vaccine preparation
The TLR4 ligand MPLA was from Avanti Polar Lipids (USA) and the TLR7
ligand guardiquimod from Chemdea (USA). DPPC, DCChol, and PHAD were
purchased from Avanti Polar Lipids; Hepes from Applichem; sucrose,
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chloroform, and ethanol from Sigma-Aldrich (Switzerland). Extruder
membranes of 400 and 200 nm pore size, as well as draining disks, were
purchased from VWR International (Switzerland). Small-scale liposome
formulations for evaluation were prepared as follows. DPPC and DCChol
stocks were prepared at 50mg/ml in methanol/methylen-chloride 1:1
(Sigma-Aldrich). Sixteen milligrams of total lipid mix was prepared and
evaporated in an Eppendorf Vacufuge. Lipids were resuspended in 1ml
20mM HEPES, 10% sucrose buffer on a shaker for 60min. Liposomes were
serially extruded using an Avanti Mini Extruder (Avanti, USA) with 400, 200,
and 100 nm membranes (Avanti). For each ﬁltration step, liposomal
solutions were passed 11 times. Large-scale liposomal formulation for the
in vivo vaccine trial were made as follows. A solution of DPPC (2.6 mL) at
30mg/mL in chloroform (78.5 mg) and 1.9 mL of a solution of DCChol at
30mg/mL in chloroform (57.3 mg) were mixed in a 50ml round-bottom
ﬂask. The solvent was evaporated with rotary evaporator (Laborota 4001,
Heidolph) at 40 °C. The lipid ﬁlm was rehydrated with 8.5 ml of pre-warmed
(40 °C) 20mM Hepes buffer containing 10% sucrose, pH 7.4, to obtain a
lipid concentration (DPPC+ DCChol) of 16 mg/ml, a DPPC concentration of
9.2 mg/ml, and DCChol concentration of 6.7 mg/ml. The mixture was
magnetically stirred for 25min and incubated for 5 min at room
temperature (RT). The mixture was inserted into an extruder (T.001,
Northern Lipids, Inc.) equipped with a thermo barrel of 10 ml and
equilibrated at 50 °C. After ﬁve extrusion cycles with a ﬁlter of pore size of
400 nm and ﬁve cycles with a ﬁlter of 200 nm, the liposome suspension
was ﬁltered through a 0.22 µm ﬁlter to recover 7.5 ml of the sterile product.
The ﬁltered product was ﬂushed with a nitrogen stream and stored at 4 °C.
Cationic liposomes containing gardiquimod were prepared with the
same procedure by rehydrating the lipid ﬁlm with 8.5 ml of pre-warmed
(40 °C) 20mM Hepes buffer containing 10% sucrose and gardiquimod at
1mg/ml, ﬁnal pH 7.4. Cationic liposomes containing MPLA were prepared
with the same procedure, except that 1.7 ml of a solution of MPLA in
chloroform at 1mg/ml was added to the chloroform solutions of DPPC and
DCChol before evaporation and formation of the lipid ﬁlm. Liposomes
were formulated with antigen to ﬁnal concentration of 8 mg/ml lipid and
20 μg/ml FMDV 146S antigen using a HEPES/Sucrose buffer under stirring.
The 146S antigen represents puriﬁed inactivated FMDV particles (sedi-
mentation coefﬁcient of 146) prepared from FMDV A Iran96 and was kindly
provided by Merial Ltd, Pirbright, UK. The antigen dose was selected as the
highest possible dose not strongly altering the physical characteristics of
the liposomal vaccine formulations (Supplementary Fig. 1).
Vaccine characterization
The liposome products were characterized immediately after preparation
by measuring pH, average particle size, polydispersion, zeta potential (light
scattering, Zetasizer Nano ZS, Malvern), and lipid component concentra-
tion (RP-HPLC, Agilent). In addition, liposomes were assessed by
transmission electron microscopy after negative staining. A droplet of
the liposome suspension diluted 1:5 in buffer was placed on a collodion/
carbon-coated 300-mesh copper grid (Electron Microscopy Sciences,
Hatﬁeld, PA). After waiting 1min to permit adsorption, excess liquid was
blotted with a ﬁlter paper and a drop of 2% phosphotungstic acid at pH 7.0
was added. After another 45 s, the negative stain was removed by
touching a ﬁlter paper to the edge of the grid. Samples were dried
overnight at RT and examined with a Philips CM12 transmission electron
microscope (FEI, The Netherlands) at an accelerating voltage of 80 kV with
primary magniﬁcations ranging from × 25,000 to × 110,000. Micrographs
were captured with a Mega View III camera using the iTEM software
version 5.2 (Olympus Soft Imaging Solutions GmbH, Münster, Germany).
For the data see Supplementary Fig. 1.
Immunization of sheep
Three groups of six Skudden sheep were immunized intramuscular with
2ml vaccine dose containing 146S antigen in PBS (PBS), antigen
formulated in liposomes (L), or antigen formulated in liposomes together
with MPLA/Gardiquimod as TLR ligands (L(TLRL)). For the group size we
performed a power analysis assuming to ﬁnd an increase of antibodies by
90% with a power of 1− β= 0.8 (80% security), with a standard error of
lower than 40%. An error ɑ of 0.05 and an error β of 0.2 was employed.
Each group was composed of three young (5–6 month of age) and three
older (1–2 years of age). Each group was composed of ﬁve females and
one castrated male. A rationale to have a such mixed group of animals was
to introduce natural variability which would also be present in ﬁeld
situations. We also reasoned that correlation analyses can only be
performed with a certain degree of variation. Serum and PBMC samples
were taken previous to vaccination and on day 3, 14, and 28. The animal
experiment was performed in accordance to the Article 18 of the Swiss
Animal Welfare Act (TSchG) and was approved by the Cantonal Ethical
Committee for animal experiments.
Serum neutralization assay
Clot activator tubes (Becton Dickinson) were used to sample serum, which
was centrifuged at 1000 × g and stored at − 20 °C until analysis. Serum was
heat-inactivated at 56 °C for 30min. Twofold serial dilutions of serum
starting with 1:10 were performed in 50 μl ﬁnal volume. Fifty microliters of
FMDV A Iran96 at 100 TCID50 was added to each well and incubated at
37 °C 5% CO2 for 1 h. Samples of vaccinated cattle were used for
standardization purpose. LFBK cells (kindly obtained from Dr. Luis
Rodriguez, Plum Island Animal Disease Center, New York, USA) were
added to wells in suspension (100 μl at 2 × 105 cells/ml) and incubated for
72 h. Cytopathic effect was used for readout. The Reed and Muench
formula was used for calculation of neutralizing titer.29 Statistical analyses
for differences in antibody responses used two-way analysis of variance
(ANOVA) combined with Tukey’s multiple comparison test.
Haptoglobin
Serum haptoglobin was measured using a the Tridelta PHASE haptoglobin
assay (Tridelta Development Ltd, Ireland). Statistical analyses for differ-
ences in haptoglobin responses used two-way ANOVA combined with
Tukey’s multiple comparison test.
Phenotyping of PBMC
Blood was collected in EDTA-coated tubes (Becton Dickinson) and PBMCs
were isolated by density centrifugation (1000 × g, 25 min) over Ficoll-Paque
(GE Healthcare, UK) using citrated blood. On D0 and D3, PBMCs from all
animals were frozen in liquid nitrogen and used for phenotyping of
monocyte and T cells populations by ﬂow cytometry. For monocyte
populations, cells were stained with anti-CD14 (IgM, CAM66A, Kingﬁsher
Biotech, MN, USA), anti-CD16 (IgG2a, KD1, Biorad) and anti-CD172a (IgG1,
DH59B, Kingﬁsher) followed by secondary conjugates including anti-
mouse IgM AlexaFluor 647, anti-mouse IgG2a AlexaFluor 488 and anti-
mouse IgG2b PECy7 (all Thermoﬁsher). Monocyte subsets were then
identiﬁed as CD14+ and CD14-CD172highCD16+ cells. For T cell
populations, PBMCs were incubated with anti-CD4 (IgG2a, 44.38, Biorad)
and anti-CD8 (IgG1, CACT80C, Kingﬁsher) antibodies followed by anti-
mouse IgG2a AlexaFluor 647 and anti-mouse IgG1 PE antibodies.
Isolation of PBMC RNA
Five million PBMCs were centrifuged at 350 × g and the pellet was
resuspended in 1ml TRIzol(R) (Thermo Fisher). RNA was isolated using the
NucleoSpin RNA kit (Macherey-Nagel, Germany). Chloroform:IAA (0.2 ml;
49:1) was added per ml of TRIzol and tubes were shaken vigorously for 15 s
followed by incubation for 3 min at RT. Then, the tubes were centrifuged at
12,000 × g, 4 °C for 15min and the aqueous phase was transferred to new
tubes and mixed with 500 μl isopropanol. After incubation for 10min at RT,
the samples were loaded on to NucleoSpin RNA columns and centrifuged
at 11,000 × g for 30 s. MDB (350 μl) was added to columns followed by
centrifugation at 11,000 × g for 30 s. DNase mixture (95 μl) was applied on
the membranes for 20min followed by washing with RAW2 buffer and
centrifugation as above. This was repeated twice with 600 μl and 250 μl
RA3 buffer, respectively. RNA was eluted with 40 μl RNase-free water and
centrifugation at 11,000 × g for 1 min. Samples were stored at − 70 °C until
analysis.
RNA-seq data analysis
The RNA quality was checked using a Fragment Analyzer. The average RIN
value of the samples is 9.1. The average insert size of the library was 446 bp
(min:413 bp, max 473 bp). The library kit used was TruSeq Stranded mRNA
from Illumina. The libraries were barcoded and 24 samples multiplexed
per sequencing lane. The libraries were single-end sequenced at 100bp.
The instrument used was an Illumina HiSeq3000 of the NGS platform of the
University of Bern (http://ngs.unibe.ch). The average number of reads per
library was 16,056,611 and their median 16,312,387. The quality of the
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reads was assessed using fastqc v.0.11.2 (http://www.bioinformatics.
babraham.ac.uk/projects/fastqc/). Ribosomal RNA (rRNA) was removed by
mapping the reads to a collection of rRNA sequences (ensembl release 3.1)
with Bowtie2 v. 2.2.1.30 The remaining reads were mapped to the Ovis aries
reference genome (Oar_v3.1) with Tophat v.2.0.13.31 We used htseq-count
v.0.6.132 to count the number of reads overlapping with each gene, as
speciﬁed in the ensembl annotation (Oar_v3.1.86). The Bioconductor
package DESeq2 v. 1.10.133 was used to test for differential gene
expression between the different time points and vaccines. As cutoff for
signiﬁcance we employed an adjusted p value of 0.05 based on the
Benjamini–Hochberg procedure. Detailed information about the genes
including the Entrez Gene ID, the description of the gene, the human
homolog ensembl gene ID and the human homolog gene name was
obtained using the Bioconductor package BioMart v. 2.26.1.34 The raw data
was uploaded to the European Nucleotide Archive accession number
PRJEB26387.
BTM analyses
To further analyze the molecular signatures of the response to different
vaccines, we performed a GSEA using blood transcription modules deﬁned
by Li et. al.1 These modules are composed of 9 up to 347 different genes.
Modules were translated to Ensembl annotation and some genes lacking
human homolog gene name were manually added to allow higher
coverage. To this end we employed Biomart (www.ensembl.org/info/data/
biomart) to create a list of putative sheep homologue Ensembl numbers.
All genes known to differ in name for human and sheep were replaced by
the sheep homologues if sufﬁcient information was found. This included
MHC, CD1, TCR, Ig and IFN genes. We also completed the list with many
genes not annotated, focussing on those represented in many BTM. Ovine
genes with high homology (>80) to another mammal were manually
annotated and included in the BTM. Human genes without HGNC symbol
in the original BTM list published by Li et al.1 were removed as most of
them were found to be either withdrawn, represent non-coding RNAs or
pseudogenes. The composition of sheep BTM can be downloaded from
the Supplementary Material. The GSEA tool (software.broadinsititute.org)35
was used to calculate enrichment scores for BTMs with each individual
animal. Signiﬁcant modules were deﬁned using p < 0.05 corrected for
multiple testing by false discovery rate q < 0.05. Pearson’s correlation of
enrichment scores with antibody or haptoglobin levels was calculated in R.
GSEA was also used to compare to compare the different vaccines. To this
end, a grouped GSEA was performed. P < 0.05 was considered signiﬁcant.
To analyze difference in high and low antibody responders, animals in
each vaccine group having an SNT at day 28 of >50% above the median
were arbitrarily deﬁned as “high responders” (n= 6) and those with < 50%
of the median as “low responders” (n= 6). Two animals per vaccine group
ﬁtted into each these criteria. Then GSEA was used to compare BTM levels
found in high and low responders. Heatmaps, scatter plots, and polar plots
were created using the ggplot 2 package or Graphpad Prism 7.0.
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